These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 6017141)

  • 21. Study of Healthcare Personnel with Influenza and other Respiratory Viruses in Israel (SHIRI): study protocol.
    Hirsch A; Katz MA; Laufer Peretz A; Greenberg D; Wendlandt R; Shemer Avni Y; Newes-Adeyi G; Gofer I; Leventer-Roberts M; Davidovitch N; Rosenthal A; Gur-Arie R; Hertz T; Glatman-Freedman A; Monto AS; Azziz-Baumgartner E; Ferdinands JM; Martin ET; Malosh RE; Neyra Quijandría JM; Levine M; Campbell W; Balicer R; Thompson MG;
    BMC Infect Dis; 2018 Nov; 18(1):550. PubMed ID: 30400834
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long-term and cross-reactive immunogenicity of inactivated trivalent influenza vaccine in the elderly: MF59-adjuvanted vaccine versus unadjuvanted vaccine.
    Song JY; Cheong HJ; Noh JY; Seo YB; Choi WS; Cho GJ; Hwang TG; Kim WJ
    J Med Virol; 2013 Sep; 85(9):1591-7. PubMed ID: 23852684
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Moving the needle on nursing staff influenza vaccination in long-term care: Results of an evidence-based intervention.
    Ofstead CL; Amelang MR; Wetzler HP; Tan L
    Vaccine; 2017 Apr; 35(18):2390-2395. PubMed ID: 28351733
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Epidemiologic studies on influenza in familial and general population groups, 1951-1956. V. Effectiveness of adjuvant vaccines.
    Philip RN; Bell JA; Davis DJ; Beem MO; Beigelman PM; Engler JI; Mellin GW; Johnson JH; Lerner AM
    Am J Epidemiol; 1969 Dec; 90(6):471-83. PubMed ID: 5362857
    [No Abstract]   [Full Text] [Related]  

  • 25. The safety and immunogenicity of a MF59-adjuvanted H5N1 prepandemic influenza vaccine in healthy adults primed with homologous or heterologous H5N1 vaccines: an observational study.
    Wei SH; Liu MT; Tsai YC; Liao CH; Chen CM; Wang WY; Huang YL; Chang FY; Chou P
    BMC Infect Dis; 2014 Nov; 14():587. PubMed ID: 25394941
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of apoptosis-associated speck-like protein containing a caspase recruitment domain on vaccine efficacy: Overcoming the effects of its deficiency with aluminum hydroxide adjuvant.
    Lee DK; Lee EY; Kim RH; Kwak HW; Kim JY; Kim H; Kang KW; Lee SM; Park JH; Chang J; Nam JH
    Microbiol Immunol; 2018 Mar; 62(3):176-186. PubMed ID: 29315762
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Influenza vaccination. The importance of antigen amount and adjuvant with reference to the humoral antibody formation after influenza vaccination. A comparative double-blind study with various vaccines].
    Sarateanu DE; Ehrengut W
    Fortschr Med; 1981 Sep; 99(34):1348-52. PubMed ID: 7026399
    [No Abstract]   [Full Text] [Related]  

  • 28. [Introduction to novel vaccine adjuvants and their role in influenza vaccination].
    Haensler J
    Ann Pharm Fr; 2013 Mar; 71(2):104-8. PubMed ID: 23537411
    [TBL] [Abstract][Full Text] [Related]  

  • 29. New Wisdom to Defy an Old Enemy: Summary from a scientific symposium at the 4th Influenza Vaccines for the World (IVW) 2012 Congress, 11 October, Valencia, Spain.
    Poland GA; Fleming DM; Treanor JJ; Maraskovsky E; Luke TC; Ball EM; Poland CM
    Vaccine; 2013 Apr; 31 Suppl 1():A1-20. PubMed ID: 23587330
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immunogenicity of avian influenza A/Anhui/01/2005(H5N1) vaccine with MF59 adjuvant: a randomized clinical trial.
    Belshe RB; Frey SE; Graham IL; Anderson EL; Jackson LA; Spearman P; Edupuganti S; Mulligan MJ; Rouphael N; Winokur P; Dolor RJ; Woods CW; Walter EB; Chen WH; Turley C; Edwards KM; Creech CB; Hill H; Bellamy AR;
    JAMA; 2014 Oct; 312(14):1420-8. PubMed ID: 25291578
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A randomized clinical trial to identify the optimal antigen and MF59(®) adjuvant dose of a monovalent A/H1N1 pandemic influenza vaccine in healthy adult and elderly subjects.
    Hatz C; von Sonnenburg F; Casula D; Lattanzi M; Leroux-Roels G
    Vaccine; 2012 May; 30(23):3470-7. PubMed ID: 22446638
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Vaccination coverage against influenza and pneumococcus for patients admitted to a pulmonary care service].
    Vandenbos F; Gal J; Radicchi B
    Rev Mal Respir; 2013 Nov; 30(9):746-51. PubMed ID: 24267764
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Epidemiological studies on influenza in familial and general population groups. I. Preliminary report on studies with adjuvant vaccines.
    PHILIP RN; BELL JA; DAVIS DJ; BEEM MO; BEIGELMAN PM
    Am J Public Health Nations Health; 1954 Jan; 44(1):34-42. PubMed ID: 13114482
    [No Abstract]   [Full Text] [Related]  

  • 34. Intranasal Inactivated Influenza Vaccines: a Reasonable Approach to Improve the Efficacy of Influenza Vaccine?
    Tamura S; Ainai A; Suzuki T; Kurata T; Hasegawa H
    Jpn J Infect Dis; 2016; 69(3):165-79. PubMed ID: 27212584
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluation of influenza vaccination in health-care workers, using rapid antigen detection test.
    Ito Y; Sumi H; Kato T
    J Infect Chemother; 2006 Apr; 12(2):70-2. PubMed ID: 16648945
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of a novel microcrystalline tyrosine adjuvant with aluminium hydroxide for enhancing vaccination against seasonal influenza.
    Heath MD; Swan NJ; Marriott AC; Silman NJ; Hallis B; Prevosto C; Gooch KE; Skinner MA
    BMC Infect Dis; 2017 Mar; 17(1):232. PubMed ID: 28347293
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Protection against Hong Kong influneza by adjuvant vaccine containing A2-Ann Arbor-67.
    Eickhoff TC; Meiklejohn G
    Bull World Health Organ; 1969; 41(3):562-3. PubMed ID: 5309476
    [No Abstract]   [Full Text] [Related]  

  • 38. Oil-in-water emulsion adjuvant with influenza vaccine in young children.
    Vesikari T; Knuf M; Wutzler P; Karvonen A; Kieninger-Baum D; Schmitt HJ; Baehner F; Borkowski A; Tsai TF; Clemens R
    N Engl J Med; 2011 Oct; 365(15):1406-16. PubMed ID: 21995388
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Priming with AS03 A-adjuvanted H5N1 influenza vaccine improves the kinetics, magnitude and durability of the immune response after a heterologous booster vaccination: an open non-randomised extension of a double-blind randomised primary study.
    Leroux-Roels I; Roman F; Forgus S; Maes C; De Boever F; Dramé M; Gillard P; van der Most R; Van Mechelen M; Hanon E; Leroux-Roels G
    Vaccine; 2010 Jan; 28(3):849-57. PubMed ID: 19835828
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy, immunogenicity, and safety evaluation of an MF59-adjuvanted quadrivalent influenza virus vaccine compared with non-adjuvanted influenza vaccine in children: a multicentre, randomised controlled, observer-blinded, phase 3 trial.
    Vesikari T; Kirstein J; Devota Go G; Leav B; Ruzycky ME; Isakov L; de Bruijn M; Oberye J; Heijnen E
    Lancet Respir Med; 2018 May; 6(5):345-356. PubMed ID: 29631857
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.